Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06842355 · ClinicalTrials.gov registry record · Phase 2
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
A Phase 2 study of Achondroplasia, sponsored by Tyra Biosciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
- 13
- Study locations
NCT06842355 is a Phase 2 study of Achondroplasia that is actively recruiting participants, run by Tyra Biosciences. The registered enrollment target is 92 participants, below the 141-participant average among 9 other Achondroplasia trials with a reported enrollment target (35% lower). The trial reports 13 study locations across 11 states.
The verdict
NCT06842355, a Phase 2 study of Achondroplasia, is actively recruiting participants, sponsored by Tyra Biosciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and identify potentially effective dose(s) of TYRA-300 in children with achondroplasia with open growth plates.
Conditions Studied
Interventions
- DRUG TYRA-300 0.125 mg/kg
- DRUG TYRA-300 0.25 mg/kg
- DRUG TYRA-300 0.375 mg/kg
- DRUG TYRA-300 0.50 mg/kg
Study Locations (13)
Maryland
- Johns Hopkins University School of Medicine - Baltimore
- Uncommon Cures - Chevy Chase
Missouri
- University of Missouri - Columbia
- Washington University - St Louis
California
- Lundquist Institute for Biomedical Innovation - Torrance
Colorado
- Children's Hospital Colorado - Aurora
Delaware
- Nemours Alfred I duPont Hospital for Children - Wilmington
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- Children's Medical Center, Dallas - Dallas
Wisconsin
- University of Wisconsin-Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2025-03-04 |
| Est. Completion | 2030-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06842355
The ClinicalTrials.gov registry entry for NCT06842355 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 141-participant average among 9 other Achondroplasia trials with a reported enrollment target (35% lower). The listed sponsor is Tyra Biosciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Achondroplasia appearing as the primary indexed condition, and to 4 interventions - of which TYRA-300 0.125 mg/kg is the first listed.
NCT06842355 reports 13 study locations spanning 11 distinct geographic areas - top geographies include Maryland, Missouri, California.
Frequently Asked Questions
What is clinical trial NCT06842355 about?
NCT06842355 is a clinical study titled "A Study of TYRA-300 in Children With Achondroplasia: BEACH301". The purpose of this study is to evaluate the safety, tolerability, and identify potentially effective dose(s) of TYRA-300 in children with achondroplasia with open growth plates.
What is the current status of trial NCT06842355?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2025-03-04. Estimated completion is 2030-06.
What conditions does trial NCT06842355 study?
This clinical trial studies the following conditions: Achondroplasia.
What interventions are being tested in trial NCT06842355?
The interventions under investigation include: TYRA-300 0.125 mg/kg (DRUG), TYRA-300 0.25 mg/kg (DRUG), TYRA-300 0.375 mg/kg (DRUG), TYRA-300 0.50 mg/kg (DRUG).
Who is sponsoring clinical trial NCT06842355?
This trial is sponsored by Tyra Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06842355 being conducted?
This trial has 13 study locations across California, Colorado, Delaware, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Achondroplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
RECRUITING · Phase 2
-
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
RECRUITING · Phase 2
-
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)
ACTIVE NOT RECRUITING · Phase 2
-
VIrtual STudy in Achondroplasia for the US (VISTA)
RECRUITING
-
Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.